Last updated: February 25, 2026
What is NDC 33342-0094?
The National Drug Code (NDC) 33342-0094 corresponds to a specific pharmaceutical product registered with the Food and Drug Administration (FDA). Based on available data, this NDC is associated with Ublituximab, a monoclonal antibody used to treat multiple sclerosis (MS).
Market Overview
Therapeutic Application and Market Size
Ublituximab is an anti-CD20 monoclonal antibody designed to deplete B cells in MS treatment. The potential market is driven by:
- Multiple sclerosis prevalence: Estimated at 2.8 million globally, with 400,000 in the U.S.
- Treatment adoption: Increasing preference for monoclonal antibodies owing to their efficacy.
- Competitive landscape: The drug faces competition from established therapies like Ocrelizumab (Ocrevus), Rituximab, and ofatumumab.
Regulatory Status
- FDA approval: Ublituximab is undergoing regulatory review as of Q4 2022.
- Market entry: Pending approval, anticipated launch in late 2023 or early 2024.
Competitive Dynamics
| Competitor |
Market Share (2022) |
Annual Revenue (USD) |
Approval Status |
Key Differentiator |
| Ocrelizumab (Ocrevus) |
~50% |
$4.3 billion |
Approved |
First FDA-approved MS anti-CD20 |
| Rituximab |
Estimated 20-30% |
Off-label use |
Approved (for other indications) |
Cost-effective alternative |
| Ofatumumab |
Growing |
~$400 million (2022) |
Approved for MS |
Subcutaneous administration |
Price Projections
Current Pricing (Pre-Approval)
Due to the absence of FDA approval, pricing remains speculative. Monoclonal antibody therapies generally range from $50,000 to $80,000 annually per patient.
Post-Approval Pricing Estimates
- Initial pricing range: $55,000 to $65,000 per year, aligning with drugs like Ocrevus.
- Market entry discounts: Up to 10-15% in year one to gain market share.
- Price adjustments: Expected to be influenced by competition, payer negotiations, and manufacturing costs.
Revenue Projections
| Year |
Projected Market Penetration |
Estimated Revenue (USD, billions) |
| 2024 |
5-10% |
$200 million – $600 million |
| 2025 |
15-25% |
$1.0 billion – $1.5 billion |
| 2026 |
30-40% |
$2.0 billion – $3.0 billion |
Assumptions: Launch in late 2023, steady growth, minimal discounting initially. Growth rates account for potential uptake and competition.
Factors Impacting Market and Price
- Regulatory approval timeline: Delays can shift revenue and market share.
- Insurance coverage: Payer negotiations influence accessible pricing.
- Competition: Existing drugs' market dominance limits pricing power.
- Manufacturing scale: Larger production capacity could reduce costs, enabling competitive pricing.
- Clinical efficacy and safety: Superior profiles could command premium pricing.
Key Takeaways
- NDC 33342-0094 correlates with Ublituximab, a promising MS therapy pending FDA approval.
- The pre-approval market size aligns with existing anti-CD20 MS treatments, with an estimated peak revenue potential exceeding $3 billion annually.
- Initial pricing likely mirrors competitors (~$55,000-$65,000/year), with discounts and payer negotiations shaping actual prices.
- Market entry strategies, regulatory timelines, and competitive dynamics will heavily influence long-term pricing and revenue.
FAQs
1. When is approval expected for NDC 33342-0094?
FDA approval is anticipated in late 2023 or early 2024, based on current regulatory review progress.
2. How does Ublituximab compare to Ocrevus?
Ublituximab is similar in mechanism but may offer different dosing, efficacy, or safety profiles. Clinical data will clarify competitive positioning.
3. What factors could lower the drug’s price?
High competition, payer pressure, or manufacturing efficiencies could lead to lower pricing.
4. How will biosimilars impact the market after approval?
Entry of biosimilars can significantly reduce prices and erode market share over 5-7 years.
5. What is the main driver of revenue for this drug?
Market penetration and pricing strategies in relation to existing MS therapies are primary revenue determinants.
References
- U.S. Food and Drug Administration. (2022). NDC Directory. https://www.fda.gov/drugs/ndc-directory
- IQVIA. (2022). The Impact of Monoclonal Antibodies in Multiple Sclerosis.
- EvaluatePharma. (2022). 2021 World Preview: Sales of Monoclonal Antibodies.
- Pharma Intelligence. (2022). MS Market Dynamics and Competitive Landscape.
- Centers for Disease Control and Prevention. (2022). Multiple Sclerosis Data & Statistics.
